ETHRIL 250 Drug Patent Profile
✉ Email this page to a colleague
When do Ethril 250 patents expire, and when can generic versions of Ethril 250 launch?
Ethril 250 is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in ETHRIL 250 is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ETHRIL 250?
- What are the global sales for ETHRIL 250?
- What is Average Wholesale Price for ETHRIL 250?
Summary for ETHRIL 250
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 26 |
| Patent Applications: | 1 |
| DailyMed Link: | ETHRIL 250 at DailyMed |
US Patents and Regulatory Information for ETHRIL 250
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | ETHRIL 250 | erythromycin stearate | TABLET;ORAL | 061605-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
